{"pii": "S0015028219323702", "abstracts": {"#name": "abstracts", "$": {"xmlns:ce": true, "xmlns:dm": true, "xmlns:sb": true}, "$$": [{"#name": "abstract", "$": {"lang": "en", "id": "abs0010", "view": "all", "class": "author"}, "$$": [{"#name": "abstract-sec", "$": {"id": "abssec0010", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0010"}, "_": "Objective"}, {"#name": "simple-para", "$": {"id": "abspara0010", "view": "all"}, "_": "To synthesize evidence on the most effective pharmacological interventions for bleeding reduction during open and minimally invasive myomectomy."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0015", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0015"}, "_": "Design"}, {"#name": "simple-para", "$": {"id": "abspara0015", "view": "all"}, "_": "Systematic review and network meta-analysis of randomized controlled trials (RCTs)."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0020", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0020"}, "_": "Setting"}, {"#name": "simple-para", "$": {"id": "abspara0020", "view": "all"}, "_": "Not applicable."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0025", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0025"}, "_": "Patients"}, {"#name": "simple-para", "$": {"id": "abspara0025", "view": "all"}, "_": "Trials assessing efficacy of pharmacological interventions during different types of myomectomy."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0030", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0030"}, "_": "Interventions"}, {"#name": "simple-para", "$": {"id": "abspara0030", "view": "all"}, "_": "Misoprostol, oxytocin, vasopressin, tranexamic acid (TXA), epinephrine, or ascorbic acid."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0035", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0035"}, "_": "Main Outcome Measures"}, {"#name": "simple-para", "$": {"id": "abspara0035", "view": "all"}, "_": "Intraoperative blood loss and need for blood transfusion."}]}, {"#name": "abstract-sec", "$": {"role": "results", "id": "abssec0040", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0040"}, "_": "Results"}, {"#name": "simple-para", "$": {"id": "abspara0040", "view": "all"}, "$$": [{"#name": "__text__", "_": "The present review included 26 randomized control trials (RCTs) (N = 1627). For minimally invasive procedures (9 RCTs; 474 patients), network meta-analysis showed that oxytocin (mean difference [MD] \u2212175.5 mL, 95% confidence interval [CI] \u221230.1.07, \u221249.93), ornipressin (MD \u2212149.6 mL, 95% CI \u2212 178.22, \u2212120.98), misoprostol, bupivacaine plus epinephrine, and vasopressin were effective in reducing myomectomy blood loss, but the evidence is of low quality. Ranking score of treatments included in subgroup analysis of minimally invasive myomectomy showed that oxytocin ranked first in reducing blood loss, followed by ornipressin. For open myomectomy (17 RCTs; 1,153 patients), network meta-analysis showed that vasopressin plus misoprostol (MD \u2212652.97 mL, 95% CI \u2212 1113.69, \u2212174.26), oxytocin, TXA, and misoprostol were effective; however, the evidence is of low quality. Vasopressin plus misoprostol ranked first in reducing blood loss during open myomectomy ("}, {"#name": "italic", "_": "P = ."}, {"#name": "__text__", "_": "97)."}]}]}, {"#name": "abstract-sec", "$": {"role": "conclusion", "id": "abssec0045", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0045"}, "_": "Conclusion"}, {"#name": "simple-para", "$": {"id": "abspara0045", "view": "all"}, "_": "There is low-quality evidence to support uterotonics, especially oxytocin, and peripheral vasoconstrictors as effective options in reducing blood loss and need for blood transfusion during minimally invasive myomectomy. Oxytocin is the most effective intervention in minimally invasive myomectomy. For open myomectomy, a combination of uterotonics and peripheral vasoconstrictors is needed to effectively reduce blood loss."}]}]}, {"#name": "abstract", "$": {"lang": "es", "id": "abs0012sua", "view": "all", "class": "author"}, "$$": [{"#name": "abstract-sec", "$": {"id": "abssec0052sua", "view": "all"}, "$$": [{"#name": "simple-para", "$": {"id": "abspara0570sua", "view": "all"}, "_": "Intervenci\u00f3n farmacol\u00f3gica periquir\u00fargica para la reducci\u00f3n del sangrado durante la miomectom\u00eda abierta y m\u00ednimamente invasiva: una revisi\u00f3n sistem\u00e1tica y metaan\u00e1lisis en red"}]}, {"#name": "abstract-sec", "$": {"id": "abssec0505sua", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0500sua"}, "_": "Objetivo"}, {"#name": "simple-para", "$": {"id": "abspara0575sua", "view": "all"}, "_": "Sintetizar la evidencia sobre las intervenciones farmacol\u00f3gicas m\u00e1s efectivas para la reducci\u00f3n del sangrado durante la miomectom\u00eda abierta y m\u00ednimamente invasiva."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0510sua", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0505sua"}, "_": "Dise\u00f1o"}, {"#name": "simple-para", "$": {"id": "abspara0580sua", "view": "all"}, "_": "Revisi\u00f3n sistem\u00e1tica y metaan\u00e1lisis en red de estudios aleatorizados controlados (RCTs)."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0515sua", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0510sua"}, "_": "Lugar"}, {"#name": "simple-para", "$": {"id": "abspara0585sua", "view": "all"}, "_": "No aplicable."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0520sua", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0515sua"}, "_": "Paciente(s)"}, {"#name": "simple-para", "$": {"id": "abspara0590sua", "view": "all"}, "_": "Estudios que valoran la eficacia de la intervenci\u00f3n farmacol\u00f3gica durante distintos tipos de miomectom\u00edas."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0525sua", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0520sua"}, "_": "Intervenci\u00f3n(es)"}, {"#name": "simple-para", "$": {"id": "abspara0595sua", "view": "all"}, "_": "Misoprostol, oxitocina, vasopresina, \u00e1cido tranex\u00e1mico (TXA), adrenalina o \u00e1cido asc\u00f3rbico."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0530sua", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0525sua"}, "_": "Medida(s) principal(es) de resultado"}, {"#name": "simple-para", "$": {"id": "abspara0600sua", "view": "all"}, "_": "P\u00e9rdida de sangre intraquir\u00fargica y necesidad de transfusi\u00f3n sangu\u00ednea."}]}, {"#name": "abstract-sec", "$": {"role": "results", "id": "abssec0535sua", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0530sua"}, "_": "Resultado(s)"}, {"#name": "simple-para", "$": {"id": "abspara0605sua", "view": "all"}, "_": "La presente revisi\u00f3n incluy\u00f3 26 estudios aleatorizados y controlados (RCTs) (N = 1627). Para los procedimientos m\u00ednimamente invasivos (9 RCTs; 474 pacientes), el metaan\u00e1lisis en red mostr\u00f3 que, la oxitocina (diferencia media [MD] - 175.5 mL, intervalo de confianza dl 95% [CI] - 30.1.07, - 49.93), ornipresina (MD - 149.6 mL, CI 95% - 178.22, - 120.98), misoprostol, bupivaca\u00edna m\u00e1s adrenalina y la vasopresina, fueron efectivos reduciendo la p\u00e9rdida de sangre en la miomectom\u00eda, aunque la evidencia es de baja calidad. El rango de puntuaci\u00f3n de los tratamientos incluidos en el an\u00e1lisis del subgrupo de la miomectom\u00eda m\u00ednimamente invasiva mostr\u00f3 que la oxitocina puntuaba la primera en la reducci\u00f3n de la p\u00e9rdida hem\u00e1tica, seguida de la ornipresina. Para la miomectom\u00eda abierta (17 RCTs; 1,153 pacientes), el metaan\u00e1lisis en red mostr\u00f3 que fueron efectivos la vasopresina m\u00e1s misoprostol (MD - 652.97 mL, CI 95% - 1113.69, - 174.26), oxitocina, TXA y el misoprostol, aunque la calidad de la evidencia es baja. La vasopresina m\u00e1s misoprostol puntuaron primeros en la reducci\u00f3n de la p\u00e9rdida hem\u00e1tica durante la miomectom\u00eda abierta (P = .97)."}]}, {"#name": "abstract-sec", "$": {"id": "abssec0540sua", "view": "all"}, "$$": [{"#name": "section-title", "$": {"id": "sectitle0535sua"}, "_": "Conclusi\u00f3n(es)"}, {"#name": "simple-para", "$": {"id": "abspara0610sua", "view": "all"}, "_": "Hay evidencia de baja calidad para sostener que los uterot\u00f3nicos, especialmente la oxitocina, y los vasoconstrictores perif\u00e9ricos son opciones efectivas para la reducci\u00f3n de la p\u00e9rdida hem\u00e1tica y de la necesidad de transfusi\u00f3n sangu\u00ednea durante la miomectom\u00eda m\u00ednimamente invasiva. Para la miomectom\u00eda abierta, una combinaci\u00f3n de uterot\u00f3nicos y vasoconstrictores perif\u00e9ricos es necesaria para disminuir de forma efectiva la p\u00e9rdida hem\u00e1tica."}]}]}]}}